- Home
- PARR vs SNDX Comparison
PARR vs SNDX Comparison
Compare PARR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PARR
- SNDX
- Stock Information
- Founded
- PARR 1984
- SNDX 2005
- Country
- PARR United States
- SNDX United States
- Employees
- PARR N/A
- SNDX N/A
- Industry
- PARR Integrated oil Companies
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- PARR Energy
- SNDX Health Care
- Exchange
- PARR Nasdaq
- SNDX Nasdaq
- Market Cap
- PARR 971.9M
- SNDX 1.1B
- IPO Year
- PARR N/A
- SNDX 2016
- Fundamental
- Price
- PARR $17.61
- SNDX $13.67
- Analyst Decision
- PARR Buy
- SNDX Strong Buy
- Analyst Count
- PARR 6
- SNDX 10
- Target Price
- PARR $24.50
- SNDX $36.20
- AVG Volume (30 Days)
- PARR 989.2K
- SNDX 2.6M
- Earning Date
- PARR 02-25-2025
- SNDX 02-25-2025
- Dividend Yield
- PARR N/A
- SNDX N/A
- EPS Growth
- PARR N/A
- SNDX N/A
- EPS
- PARR 5.32
- SNDX N/A
- Revenue
- PARR $8,325,746,999.00
- SNDX $16,000,000.00
- Revenue This Year
- PARR N/A
- SNDX N/A
- Revenue Next Year
- PARR N/A
- SNDX N/A
- P/E Ratio
- PARR $3.41
- SNDX N/A
- Revenue Growth
- PARR 5.96
- SNDX N/A
- 52 Week Low
- PARR $14.84
- SNDX $12.06
- 52 Week High
- PARR $40.70
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- PARR 55.92
- SNDX 48.26
- Support Level
- PARR $17.54
- SNDX $12.40
- Resistance Level
- PARR $18.21
- SNDX $13.16
- Average True Range (ATR)
- PARR 0.70
- SNDX 0.66
- MACD
- PARR 0.15
- SNDX 0.14
- Stochastic Oscillator
- PARR 59.19
- SNDX 62.16
About PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.